Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anwar Wassel

Pulmonary Disease Utica, NY Medical Doctor

NPI 1376707521 CMS profile 153451

1450 Champlin Ave, Utica, NY 13502

Open in the dashboard

General payments

$46,715

637 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anwar Wassel of Utica, NY is reported in the CMS Open Payments database as having received $46,715 across 637 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,164 90
2024 General $5,813 86
2023 General $9,723 97
2022 General $9,752 85
2021 General $13,045 110
2020 General $2,799 75
2019 General $1,419 94

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anwar Wassel
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Anwar Wassel were reported at $4,164. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Anwar Wassel Pulmonary Disease median Middle half National median
2019 $1,419 $377 $109–$1,340 $163
2020 $2,799 $230 $56–$907 $114
2021 $13,045 $269 $68–$1,072 $132
2022 $9,752 $390 $100–$1,457 $149
2023 $9,723 $419 $114–$1,659 $160
2024 $5,813 $476 $123–$1,818 $164
2025 $4,164 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $36,594 144 payments
  2. GlaxoSmithKline, LLC. $1,869 116 payments
  3. Harmony Biosciences LLC $1,151 53 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $1,003 47 payments
  5. Genzyme Corporation $801 25 payments
  6. Electromed, Inc. $732 28 payments
  7. Grifols USA, LLC $718 52 payments
  8. Jazz Pharmaceuticals Inc. $700 27 payments
  9. Regeneron Healthcare Solutions, Inc. $498 21 payments
  10. Amgen Inc. $443 20 payments
  11. Other $2,207 104 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $33,050 30 payments
  2. Food and Beverage $12,731 600 payments
  3. Consulting Fee $625 1 payment
  4. Education $285 5 payments
  5. Travel and Lodging $25 1 payment
Products named General payments · program years 2019–2025
  1. BREZTRI $33,644 61 payments
  2. BREZTRI AEROSPHERE $1,482 7 payments
  3. TRELEGY ELLIPTA $1,016 64 payments
  4. DUPIXENT $816 24 payments
  5. Prolastin-C Liquid $718 52 payments
  6. SMARTVEST $718 27 payments
  7. NUCALA $625 37 payments
  8. SPIRIVA RESPIMAT $618 30 payments
  9. OFEV $515 24 payments
  10. SYMBICORT $437 28 payments
  11. Other $7,066 327 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 47 drugs

Part D claims

2,864

Median for Pulmonary Disease: 936

Drug cost

$1,090,682

Median for Pulmonary Disease: $487,987

Branded share of claims

59.7%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 403 $284,814
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 268 $199,435
Xywav Sodium,calcium,mag,pot Oxybate Brand 13 $171,446
Ofev Nintedanib Esylate Brand 12 $147,521
Spiriva Respimat Tiotropium Bromide Brand 100 $62,733
Nucala Mepolizumab Brand 14 $46,797
Breo Ellipta Fluticasone/Vilanterol Brand 76 $33,789
Incruse Ellipta Umeclidinium Bromide Brand 47 $20,800
Symbicort Budesonide/Formoterol Fumarate Brand 56 $18,098
Eliquis Apixaban Brand 24 $14,543

The 10 drugs with the highest cost, of 47 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$229,764

Medicare's payments for the services billed

Medicare patients

591

Average age 74

Services billed

2,816

295 women, 296 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 59%
Arthritis 55%
Chronic kidney disease 51%
Diabetes 47%
Ischemic heart disease 44%
Heart failure 40%
Atrial fibrillation 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $4,088
$4,088 268 —
WAKIX
  • Harmony Biosciences LLC $305
$305 — —
DUPIXENT
  • GENZYME CORPORATION $171
  • Regeneron Healthcare Solutions, Inc. $19
$190 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $89
  • Amgen Inc. $62
$151 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $125
$125 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

637 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record